• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU 2.17% $21.22

NEUREN PHARMACEUTICALS LIMITED - Announcements

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


NEU Application for quotation of securities - NEU12/03/24 download Created with Sketch. 14.25KB
NEU 2023 Results webinar29/02/24 download Created with Sketch. 2.88MB
NEU Neuren reports profit of $157 million for 2023PRICE SENSITIVE29/02/24 download Created with Sketch. 928.21KB
NEU Appendix 4E and 2023 full year accountsPRICE SENSITIVE29/02/24 download Created with Sketch. 713.93KB
NEU Neuren 2023 results investor webinar on 29 February 202429/02/24 download Created with Sketch. 174.93KB
NEU DAYBUE net sales US$87.1 million in Q4 2023PRICE SENSITIVE28/02/24 download Created with Sketch. 451.14KB
NEU Comment on research reportPRICE SENSITIVE16/02/24 download Created with Sketch. 219.15KB
NEU Pause in TradingPRICE SENSITIVE16/02/24 download Created with Sketch. 115.14KB
NEU Notification regarding unquoted securities - NEU08/02/24 download Created with Sketch. 17.81KB
NEU Application for quotation of securities - NEU01/02/24 download Created with Sketch. 24.82KB
NEU Q4 2023 Appendix 4C Cash Flow ReportPRICE SENSITIVE31/01/24 download Created with Sketch. 154.86KB
NEU Q4 2023 quarterly activity reportPRICE SENSITIVE31/01/24 download Created with Sketch. 639.68KB
NEU Completion of enrolment in Neuren's Angelman P2 trialPRICE SENSITIVE20/12/23 download Created with Sketch. 205KB
NEU Application for quotation of securities - NEU19/12/23 download Created with Sketch. 28.11KB
NEU Investor presentation, 18 December 2023PRICE SENSITIVE18/12/23 download Created with Sketch. 2.97MB
NEU P2 trial shows significant improvements in Phelan-McDermidPRICE SENSITIVE18/12/23 download Created with Sketch. 723.12KB
NEU Trading HaltPRICE SENSITIVE14/12/23 download Created with Sketch. 198.45KB
NEU Neuren completes enrolment in Pitt Hopkins Phase 2 trialPRICE SENSITIVE05/12/23 download Created with Sketch. 188.42KB
NEU Comment on media speculation20/11/23 download Created with Sketch. 177.19KB
NEU Neuren completes Phelan-McDermid syndrome Phase 2 trial13/11/23 download Created with Sketch. 200.25KB
NEU Investor presentation, 8 November 202308/11/23 download Created with Sketch. 2MB
NEU DAYBUE net sales US$66.9 million in Q3 2023PRICE SENSITIVE03/11/23 download Created with Sketch. 209.5KB
NEU Q3 2023 quarterly activity and cash flow reportPRICE SENSITIVE20/10/23 download Created with Sketch. 556.7KB
NEU Change of Director's Interest Notice - J Basile14/09/23 download Created with Sketch. 177.21KB
NEU S&P DJI Announces September 2023 Quarterly RebalancePRICE SENSITIVE01/09/23 download Created with Sketch. 121.59KB
NEU Investor presentation, 28 August 202328/08/23 download Created with Sketch. 1.72MB
NEU Neuren reports 2023 half-year profit after tax of $48m28/08/23 download Created with Sketch. 393.66KB
NEU Half Yearly Report and AccountsPRICE SENSITIVE28/08/23 download Created with Sketch. 485.54KB
NEU Notification of half-year results & investor web conference25/08/23 download Created with Sketch. 153.58KB
NEU Q2 2023 quarterly activity and cash flow reportPRICE SENSITIVE31/07/23 download Created with Sketch. 545.93KB
NEU Neuren receives US$100m for expanded DAYBUE agreementPRICE SENSITIVE27/07/23 download Created with Sketch. 162.94KB
NEU Investor web conference presentation, 14 July 202314/07/23 download Created with Sketch. 669.71KB
NEU Neuren and Acadia expand global partnership for trofinetidePRICE SENSITIVE14/07/23 download Created with Sketch. 179.35KB
NEU Neuren completes enrolment in Phelan-McDermid Phase 2 trialPRICE SENSITIVE30/06/23 download Created with Sketch. 128.16KB
NEU Neuren opens first site in US for Prader-Willi Phase 2 trialPRICE SENSITIVE28/06/23 download Created with Sketch. 272.4KB
NEU Change of Director's Interest Notice14/06/23 download Created with Sketch. 125.7KB
NEU Neuren receives US$40m milestone paymentPRICE SENSITIVE07/06/23 download Created with Sketch. 122.47KB
NEU Neuren presenting at Jefferies Global Healthcare Conference05/06/23 download Created with Sketch. 120.13KB
NEU Results of Meeting30/05/23 download Created with Sketch. 63.25KB
NEU AGM Chair Address & CEO Presentation30/05/23 download Created with Sketch. 1.42MB
NEU Notice of Annual General Meeting/Proxy Form28/04/23 download Created with Sketch. 320.3KB
NEU Virtual AGM online guide28/04/23 download Created with Sketch. 1MB
NEU Q1 2023 quarterly activity and cash flow reportPRICE SENSITIVE28/04/23 download Created with Sketch. 331.52KB
NEU Appendix 4G27/04/23 download Created with Sketch. 149.33KB
NEU 2022 Annual Report to shareholders27/04/23 download Created with Sketch. 1.81MB
NEU DAYBUE (trofinetide) launched in US - Neuren earns US$40mPRICE SENSITIVE18/04/23 download Created with Sketch. 330.95KB
NEU Application for quotation of securities - NEU27/03/23 download Created with Sketch. 24.24KB
NEU Investor Presentation, 14 March 202314/03/23 download Created with Sketch. 1.49MB
NEU Notification of investor webinar13/03/23 download Created with Sketch. 155.1KB
NEU FDA approves Daybue - the first treatment for Rett syndromePRICE SENSITIVE13/03/23 download Created with Sketch. 258.83KB
NEU Initial Director's Interest Notice02/03/23 download Created with Sketch. 170.86KB
NEU Neuren appoints Joe Basile to board of directors02/03/23 download Created with Sketch. 120.39KB
NEU Investor presentation, 1 March 202301/03/23 download Created with Sketch. 1.54MB
NEU Investor Presentation, 24 February 202324/02/23 download Created with Sketch. 1.32MB
NEU Neuren reports 2022 full-year resultsPRICE SENSITIVE24/02/23 download Created with Sketch. 177.83KB
NEU Appendix 4E and 2022 full year accountsPRICE SENSITIVE24/02/23 download Created with Sketch. 458.57KB
NEU Application for quotation of securities - NEU21/02/23 download Created with Sketch. 24.25KB
NEU Q4 2022 quarterly activity and cash flow reportPRICE SENSITIVE31/01/23 download Created with Sketch. 278.86KB
NEU Prader-Willi syndrome IND for NNZ-2591 approved by FDAPRICE SENSITIVE23/01/23 download Created with Sketch. 149.69KB
NEU Neuren submits IND & first patients complete Phase 2 trialsPRICE SENSITIVE23/12/22 download Created with Sketch. 285.67KB
NEU Becoming a substantial holder07/12/22 download Created with Sketch. 197.83KB
NEU Ceasing to be a substantial holder02/12/22 download Created with Sketch. 90.6KB
NEU Change in substantial holding23/11/22 download Created with Sketch. 250.67KB
NEU Jefferies London Healthcare Conference 2022 presentation18/11/22 download Created with Sketch. 1.25MB
NEU Q3 2022 quarterly activity and cash flow reportPRICE SENSITIVE27/10/22 download Created with Sketch. 409.29KB
NEU Neuren receives US$10 million milestone paymentPRICE SENSITIVE20/10/22 download Created with Sketch. 147.13KB
NEU Investor presentation, 14 September 202214/09/22 download Created with Sketch. 1.38MB
NEU Rett Syndrome NDA accepted for Priority Review by FDAPRICE SENSITIVE13/09/22 download Created with Sketch. 231.46KB
NEU S&P DJI Announces September 2022 Quarterly RebalancePRICE SENSITIVE02/09/22 download Created with Sketch. 134KB
NEU Half-year shareholder update24/08/22 download Created with Sketch. 283.08KB
NEU Half Yearly Report and AccountsPRICE SENSITIVE24/08/22 download Created with Sketch. 338.87KB
NEU Investor presentation, 8 August 202208/08/22 download Created with Sketch. 1.18MB
NEU Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHSPRICE SENSITIVE08/08/22 download Created with Sketch. 178.95KB
NEU Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE29/07/22 download Created with Sketch. 349.07KB
NEU Acadia submits Rett Syndrome New Drug Application to the FDAPRICE SENSITIVE19/07/22 download Created with Sketch. 309.46KB
NEU Neuren commences Phase 2 trial of NNZ-2591 in AngelmanPRICE SENSITIVE12/07/22 download Created with Sketch. 154.47KB
NEU Notification regarding unquoted securities - NEU08/07/22 download Created with Sketch. 27.75KB
NEU Neuren appoints Chief Medical Officer in United StatesPRICE SENSITIVE08/07/22 download Created with Sketch. 150.09KB
NEU Results of Meeting30/05/22 download Created with Sketch. 63.57KB
NEU AGM Chairman's Address & CEO Presentation30/05/22 download Created with Sketch. 683.09KB
NEU Quarterly Activities/Appendix 4C Cash Flow ReportPRICE SENSITIVE29/04/22 download Created with Sketch. 276.23KB
NEU Virtual AGM online guide28/04/22 download Created with Sketch. 1MB
NEU Notice of Annual General Meeting/Proxy Form28/04/22 download Created with Sketch. 781.61KB
NEU Change in substantial holding27/04/22 download Created with Sketch. 235.82KB
NEU Appendix 4G27/04/22 download Created with Sketch. 146.25KB
NEU Annual Report to shareholders27/04/22 download Created with Sketch. 1.72MB
NEU FDA approval for Pitt Hopkins syndrome IND and Phase 2 trialPRICE SENSITIVE25/03/22 download Created with Sketch. 151.55KB
NEU FDA approval for Phelan-McDermid IND and Phase 2 trialPRICE SENSITIVE23/03/22 download Created with Sketch. 152.68KB
NEU Ethics approval for Angelman Phase 2 trial in AustraliaPRICE SENSITIVE11/03/22 download Created with Sketch. 152.94KB
NEU S&P DJI Announces March 2022 Quarterly RebalancePRICE SENSITIVE04/03/22 download Created with Sketch. 175.5KB
NEU Investor presentation 25 Feb 202225/02/22 download Created with Sketch. 886.27KB
NEU FDA approval for Angelman IND and Phase 2 trialPRICE SENSITIVE25/02/22 download Created with Sketch. 154.3KB
NEU 2021 Results - a transformational year for NeurenPRICE SENSITIVE24/02/22 download Created with Sketch. 175.8KB
NEU Preliminary Final Report and 2021 Full Year AccountsPRICE SENSITIVE24/02/22 download Created with Sketch. 486.79KB
NEU Notification regarding unquoted securities - NEU03/02/22 download Created with Sketch. 28.31KB
NEU Neuren appoints Vice President, Corporate Development01/02/22 download Created with Sketch. 147.8KB
NEU Q4 2021 quarterly activity and cash flow reportPRICE SENSITIVE31/01/22 download Created with Sketch. 339.96KB
NEU Becoming a substantial holder10/12/21 download Created with Sketch. 200.6KB
NEU Positive topline results from Phase 3 trial in Rett syndromePRICE SENSITIVE07/12/21 download Created with Sketch. 174.6KB
NEU Neuren presenting at Bell Potter Healthcare Conference10/11/21 download Created with Sketch. 719.92KB
NEU Application for quotation of securities - NEU
12/03/24 download Created with Sketch. 14.25KB
NEU 2023 Results webinar
29/02/24 download Created with Sketch. 2.88MB
NEU Neuren reports profit of $157 million for 2023
29/02/24PRICE SENSITIVE download Created with Sketch. 928.21KB
NEU Appendix 4E and 2023 full year accounts
29/02/24PRICE SENSITIVE download Created with Sketch. 713.93KB
NEU Neuren 2023 results investor webinar on 29 February 2024
29/02/24 download Created with Sketch. 174.93KB
NEU DAYBUE net sales US$87.1 million in Q4 2023
28/02/24PRICE SENSITIVE download Created with Sketch. 451.14KB
NEU Comment on research report
16/02/24PRICE SENSITIVE download Created with Sketch. 219.15KB
NEU Pause in Trading
16/02/24PRICE SENSITIVE download Created with Sketch. 115.14KB
NEU Notification regarding unquoted securities - NEU
08/02/24 download Created with Sketch. 17.81KB
NEU Application for quotation of securities - NEU
01/02/24 download Created with Sketch. 24.82KB
NEU Q4 2023 Appendix 4C Cash Flow Report
31/01/24PRICE SENSITIVE download Created with Sketch. 154.86KB
NEU Q4 2023 quarterly activity report
31/01/24PRICE SENSITIVE download Created with Sketch. 639.68KB
NEU Completion of enrolment in Neuren's Angelman P2 trial
20/12/23PRICE SENSITIVE download Created with Sketch. 205KB
NEU Application for quotation of securities - NEU
19/12/23 download Created with Sketch. 28.11KB
NEU Investor presentation, 18 December 2023
18/12/23PRICE SENSITIVE download Created with Sketch. 2.97MB
NEU P2 trial shows significant improvements in Phelan-McDermid
18/12/23PRICE SENSITIVE download Created with Sketch. 723.12KB
NEU Trading Halt
14/12/23PRICE SENSITIVE download Created with Sketch. 198.45KB
NEU Neuren completes enrolment in Pitt Hopkins Phase 2 trial
05/12/23PRICE SENSITIVE download Created with Sketch. 188.42KB
NEU Comment on media speculation
20/11/23 download Created with Sketch. 177.19KB
NEU Neuren completes Phelan-McDermid syndrome Phase 2 trial
13/11/23 download Created with Sketch. 200.25KB
NEU Investor presentation, 8 November 2023
08/11/23 download Created with Sketch. 2MB
NEU DAYBUE net sales US$66.9 million in Q3 2023
03/11/23PRICE SENSITIVE download Created with Sketch. 209.5KB
NEU Q3 2023 quarterly activity and cash flow report
20/10/23PRICE SENSITIVE download Created with Sketch. 556.7KB
NEU Change of Director's Interest Notice - J Basile
14/09/23 download Created with Sketch. 177.21KB
NEU S&P DJI Announces September 2023 Quarterly Rebalance
01/09/23PRICE SENSITIVE download Created with Sketch. 121.59KB
NEU Investor presentation, 28 August 2023
28/08/23 download Created with Sketch. 1.72MB
NEU Neuren reports 2023 half-year profit after tax of $48m
28/08/23 download Created with Sketch. 393.66KB
NEU Half Yearly Report and Accounts
28/08/23PRICE SENSITIVE download Created with Sketch. 485.54KB
NEU Notification of half-year results & investor web conference
25/08/23 download Created with Sketch. 153.58KB
NEU Q2 2023 quarterly activity and cash flow report
31/07/23PRICE SENSITIVE download Created with Sketch. 545.93KB
NEU Neuren receives US$100m for expanded DAYBUE agreement
27/07/23PRICE SENSITIVE download Created with Sketch. 162.94KB
NEU Investor web conference presentation, 14 July 2023
14/07/23 download Created with Sketch. 669.71KB
NEU Neuren and Acadia expand global partnership for trofinetide
14/07/23PRICE SENSITIVE download Created with Sketch. 179.35KB
NEU Neuren completes enrolment in Phelan-McDermid Phase 2 trial
30/06/23PRICE SENSITIVE download Created with Sketch. 128.16KB
NEU Neuren opens first site in US for Prader-Willi Phase 2 trial
28/06/23PRICE SENSITIVE download Created with Sketch. 272.4KB
NEU Change of Director's Interest Notice
14/06/23 download Created with Sketch. 125.7KB
NEU Neuren receives US$40m milestone payment
07/06/23PRICE SENSITIVE download Created with Sketch. 122.47KB
NEU Neuren presenting at Jefferies Global Healthcare Conference
05/06/23 download Created with Sketch. 120.13KB
NEU Results of Meeting
30/05/23 download Created with Sketch. 63.25KB
NEU AGM Chair Address & CEO Presentation
30/05/23 download Created with Sketch. 1.42MB
NEU Notice of Annual General Meeting/Proxy Form
28/04/23 download Created with Sketch. 320.3KB
NEU Virtual AGM online guide
28/04/23 download Created with Sketch. 1MB
NEU Q1 2023 quarterly activity and cash flow report
28/04/23PRICE SENSITIVE download Created with Sketch. 331.52KB
NEU Appendix 4G
27/04/23 download Created with Sketch. 149.33KB
NEU 2022 Annual Report to shareholders
27/04/23 download Created with Sketch. 1.81MB
NEU DAYBUE (trofinetide) launched in US - Neuren earns US$40m
18/04/23PRICE SENSITIVE download Created with Sketch. 330.95KB
NEU Application for quotation of securities - NEU
27/03/23 download Created with Sketch. 24.24KB
NEU Investor Presentation, 14 March 2023
14/03/23 download Created with Sketch. 1.49MB
NEU Notification of investor webinar
13/03/23 download Created with Sketch. 155.1KB
NEU FDA approves Daybue - the first treatment for Rett syndrome
13/03/23PRICE SENSITIVE download Created with Sketch. 258.83KB
NEU Initial Director's Interest Notice
02/03/23 download Created with Sketch. 170.86KB
NEU Neuren appoints Joe Basile to board of directors
02/03/23 download Created with Sketch. 120.39KB
NEU Investor presentation, 1 March 2023
01/03/23 download Created with Sketch. 1.54MB
NEU Investor Presentation, 24 February 2023
24/02/23 download Created with Sketch. 1.32MB
NEU Neuren reports 2022 full-year results
24/02/23PRICE SENSITIVE download Created with Sketch. 177.83KB
NEU Appendix 4E and 2022 full year accounts
24/02/23PRICE SENSITIVE download Created with Sketch. 458.57KB
NEU Application for quotation of securities - NEU
21/02/23 download Created with Sketch. 24.25KB
NEU Q4 2022 quarterly activity and cash flow report
31/01/23PRICE SENSITIVE download Created with Sketch. 278.86KB
NEU Prader-Willi syndrome IND for NNZ-2591 approved by FDA
23/01/23PRICE SENSITIVE download Created with Sketch. 149.69KB
NEU Neuren submits IND & first patients complete Phase 2 trials
23/12/22PRICE SENSITIVE download Created with Sketch. 285.67KB
NEU Becoming a substantial holder
07/12/22 download Created with Sketch. 197.83KB
NEU Ceasing to be a substantial holder
02/12/22 download Created with Sketch. 90.6KB
NEU Change in substantial holding
23/11/22 download Created with Sketch. 250.67KB
NEU Jefferies London Healthcare Conference 2022 presentation
18/11/22 download Created with Sketch. 1.25MB
NEU Q3 2022 quarterly activity and cash flow report
27/10/22PRICE SENSITIVE download Created with Sketch. 409.29KB
NEU Neuren receives US$10 million milestone payment
20/10/22PRICE SENSITIVE download Created with Sketch. 147.13KB
NEU Investor presentation, 14 September 2022
14/09/22 download Created with Sketch. 1.38MB
NEU Rett Syndrome NDA accepted for Priority Review by FDA
13/09/22PRICE SENSITIVE download Created with Sketch. 231.46KB
NEU S&P DJI Announces September 2022 Quarterly Rebalance
02/09/22PRICE SENSITIVE download Created with Sketch. 134KB
NEU Half-year shareholder update
24/08/22 download Created with Sketch. 283.08KB
NEU Half Yearly Report and Accounts
24/08/22PRICE SENSITIVE download Created with Sketch. 338.87KB
NEU Investor presentation, 8 August 2022
08/08/22 download Created with Sketch. 1.18MB
NEU Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
08/08/22PRICE SENSITIVE download Created with Sketch. 178.95KB
NEU Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22PRICE SENSITIVE download Created with Sketch. 349.07KB
NEU Acadia submits Rett Syndrome New Drug Application to the FDA
19/07/22PRICE SENSITIVE download Created with Sketch. 309.46KB
NEU Neuren commences Phase 2 trial of NNZ-2591 in Angelman
12/07/22PRICE SENSITIVE download Created with Sketch. 154.47KB
NEU Notification regarding unquoted securities - NEU
08/07/22 download Created with Sketch. 27.75KB
NEU Neuren appoints Chief Medical Officer in United States
08/07/22PRICE SENSITIVE download Created with Sketch. 150.09KB
NEU Results of Meeting
30/05/22 download Created with Sketch. 63.57KB
NEU AGM Chairman's Address & CEO Presentation
30/05/22 download Created with Sketch. 683.09KB
NEU Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22PRICE SENSITIVE download Created with Sketch. 276.23KB
NEU Virtual AGM online guide
28/04/22 download Created with Sketch. 1MB
NEU Notice of Annual General Meeting/Proxy Form
28/04/22 download Created with Sketch. 781.61KB
NEU Change in substantial holding
27/04/22 download Created with Sketch. 235.82KB
NEU Appendix 4G
27/04/22 download Created with Sketch. 146.25KB
NEU Annual Report to shareholders
27/04/22 download Created with Sketch. 1.72MB
NEU FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
25/03/22PRICE SENSITIVE download Created with Sketch. 151.55KB
NEU FDA approval for Phelan-McDermid IND and Phase 2 trial
23/03/22PRICE SENSITIVE download Created with Sketch. 152.68KB
NEU Ethics approval for Angelman Phase 2 trial in Australia
11/03/22PRICE SENSITIVE download Created with Sketch. 152.94KB
NEU S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22PRICE SENSITIVE download Created with Sketch. 175.5KB
NEU Investor presentation 25 Feb 2022
25/02/22 download Created with Sketch. 886.27KB
NEU FDA approval for Angelman IND and Phase 2 trial
25/02/22PRICE SENSITIVE download Created with Sketch. 154.3KB
NEU 2021 Results - a transformational year for Neuren
24/02/22PRICE SENSITIVE download Created with Sketch. 175.8KB
NEU Preliminary Final Report and 2021 Full Year Accounts
24/02/22PRICE SENSITIVE download Created with Sketch. 486.79KB
NEU Notification regarding unquoted securities - NEU
03/02/22 download Created with Sketch. 28.31KB
NEU Neuren appoints Vice President, Corporate Development
01/02/22 download Created with Sketch. 147.8KB
NEU Q4 2021 quarterly activity and cash flow report
31/01/22PRICE SENSITIVE download Created with Sketch. 339.96KB
NEU Becoming a substantial holder
10/12/21 download Created with Sketch. 200.6KB
NEU Positive topline results from Phase 3 trial in Rett syndrome
07/12/21PRICE SENSITIVE download Created with Sketch. 174.6KB
NEU Neuren presenting at Bell Potter Healthcare Conference
10/11/21 download Created with Sketch. 719.92KB
(20min delay)
Last
$21.22
Change
0.450(2.17%)
Mkt cap ! $2.705B
Open High Low Value Volume
$20.76 $21.43 $20.70 $7.917M 374.9K

Buyers (Bids)

No. Vol. Price($)
1 240 $20.75
 

Sellers (Offers)

Price($) Vol. No.
$21.30 1000 1
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
$21.24
  Change
0.450 ( 2.73 %)
Open High Low Volume
$20.76 $21.42 $20.73 102057
Last updated 15.59pm 29/03/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.